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A novel mechanism-based mammalian cell assay for the 
identification of SH2-domain-specific protein-protein inhibitors 
Richard J Rickles, Pamela A Henry, Wei Guan, Mihai Azimioara, 
William C Shakespeare, Shelia Violette and Mark J Zoller 
Background: Many intracellular signal-transduction pathways are regulated by 
specific protein-protein interactions. These interactions are mediated by 
structural domains within signaling proteins that modulate a protein’s cellular 
location, stability or activity. For example, Src-homology 2 (SH2) domains 
mediate protein-protein interactions through short contiguous amino acid 
motifs containing phosphotyrosine. As SH2 domains have been recognized as 
key regulatory molecules in a variety of cellular processes, they have become 
attractive drug targets. 
Results: We have developed a novel mechanism-based cellular assay to 
monitor specific SHP-domain-dependent protein-protein interactions. The 
assay is based on a two-hybrid system adapted to function in mammalian cells 
where the SH2 domain ligand is phosphorylated, and binding to a specific SH2 
domain can be induced and easily monitored. As examples, we have generated 
a series of mammalian cell lines that can be used to monitor SH2-domain- 
dependent activity of the signaling proteins ZAP-70 and Src. We are utilizing 
these cell lines to screen for immunosuppressive and anti-osteoclastic 
compounds, respectively, and demonstrate here the utility of this system for the 
identification-of small-molecule, cell-permeant SH2 domain inhibitors. 
Conclusions: A mechanism-based mammalian cell assay has been developed 
to identify inhibitors of SHP-domain-dependent protein-protein interactions, 
Mechanism-based assays similar to that described here might have general use 
as screens for cell-permeant, nontoxic inhibitors of protein-protein interactions. 
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Introduction 
Changes in cellular activity are triggered as a physiological 
response to environmental and developmental conditions. 
The mediators of these responses include small mol- 
ecules, ions, peptides and cell surfaces. The relay of 
signals within the cell occurs via a cascade of specific mol- 
ecular interactions, involving proteins that have either 
enzymatic or binding activity [l,Z]. During the past 15 
years, many components of pathways regulated by a 
variety of mediators have been elucidated. This knowl- 
edge is being applied to the development of pharmaceuti- 
cal agents that interfere with signal transduction for the 
treatment or prevention of disease [3,4]. Many of the sig- 
naling pathways have redundancies, where multiple pro- 
teins of a gene family will simultaneously perform 
overlapping functions or parallel distinct signaling events 
take place to yield the same net result. The ability to 
target unique and essential steps of a given signal cascade 
provides a means to discover new therapeutic agents that 
are effective and safe. 
Targeted disruption of genes in mice, as well as clinical, 
genetic and biochemical studies of human diseases, has 
provided important information about signaling proteins 
essential for basic biological processes. For example, 
studies on mice that are deficient in Src have revealed 
that the Src tyrosine kinase is essential for osteoclast- 
mediated bone resorption [S]. As the Src SH2 and SH3 
domains mediate important protein-protein interactions 
[6], molecules that antagonize Src SHZ or SH3 domain 
function might inhibit bone resorption and therefore 
could be useful for the treatment of osteoporosis. ZAP-70 
is another essential signaling protein. Humans lacking 
ZAP-70, a T-cell-receptor (TCR)-associated protein tyro- 
sine kinase, have a form of severe combined immunodefi- 
ciency syndrome [7,8]. Individuals lacking ZAP-70 
exhibit defective TCR-dependent signal transduction 
and abnormal T-cell development. ZAP-70-deficient 
mice have a similar phenotype [9]. ZAP-70 contains two 
SH2 domains that mediate the association of ZAP-70 with 
immunoregulatory tyrosine-activation motifs (ITAMs) 
present in the cytoplasmic domains of the TCR [lo]. 
TCR ligation induces ITAM-bound ZAP-70 tyrosine 
phosphorylation and kinase activity. Molecules that block 
the binding of ZAP-70 SH2 domains to ITAMs inhibit 
T-cell activation [ll]. As defects in ZAP-70 function 
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Conditions for tandem ZAP-70 SH2 domain-l; 
two-hybrid formation in mammalian cells. 
5 x GAL4 IL-2 SEAP HTlO80 cells were 
transfected with the effector plasmids 
described in the text. Following transfection, 
cells were cultured for 24 h and the media 
were then assayed for SEAP. Mock 
transfected cells received carrier DNA and no 
effector plasmids. The results from two 
transfections are shown (a,b). The SEAP 
assay was performed for 1 h at 37%. SEAP 
activity is given as relative arbitrary units. G, 
GAL4 (DNA-binding domain, residues 
l-l 47); VP, VP1 6 transcriptional activation 
domain; GVP, GAL4-VP16; GZ22, 
GAL4-ZAP SH2 domains; VPSZ, VP1 6-Src-, 
kinase-6 ITAM; GS, GAL4-Src-kinase; GSZ, 
GAL4-Src-kinase-< ITAM. 
compromise T-cell function, pharmaceutical agents that 
selectively block ZAP-70 SH’2 domain binding would be 
immunosuppressive agents. 
Our goal has been to identify inhibitors of specific SHZ- 
domain-dependent protein-protein interactions using an 
in a& screening assay. Such molecules would be ideal 
pharmacological agents. A cellular assay offers the 
advantage over an in vitro assay of identifying cell-per- 
meant compounds and allowing an assessment of non- 
specific effects on cellular functions. Mammalian cells 
are preferable for our purposes because the permeability 
of compounds into yeast cells is often not the same as 
that into mammalian cells [l&14]. Given the plethora of 
SHZ-domain-containing proteins in a mammalian cell, 
the identification of specific inhibitors requires the use 
of a mechanism-based screen. One technique, the two- 
hybrid interaction assay, is a widely used method for 
identifying interacting proteins [l&16]. The two-hybrid 
method is typically performed using yeast cells to iden- 
tify the association of known proteins with unidentified 
cellular proteins and to map determinants within pro- 
teins important for protein-protein interactions [l&16]. 
This assay is based on the interaction of hybrid tran- 
scription factors. One protein (the target protein) is 
fused to a DNA-binding domain and a second, interact- 
ing protein (or cDNA if it is a library screen) is fused to a 
transcriptional activation domain. The two proteins are 
coexpressed in cells that contain a reporter gene with 
upstream cognate binding sites for the DNA-binding 
domain. If the two chimeric proteins interact, the 
reporter gene will be transcriptionally activated, allowing 
detection of the interaction. 
Here, we have modified the two-hybrid assay to develop 
a mechanism-based cellular assay for inhibitors of SHZ- 
dependent interactions. The SHZ domain and ligand 
were expressed in a mammalian cell line as components 
of molecules used for a two-hybrid interaction screen. 
The application of the two-hybrid assay to SHZ-domain- 
peptide-ligand interactions is complicated by the need to 
phosphorylate the ligand on tyrosine. The hybrid mol- 
ecules have therefore been engineered such that the 
binding partner is tyrosine phosphorylated, so that it 
serves as a good binding site for the SHZ domain. Both 
the effector and reporter gene plasmids have been stably 
integrated into mammalian cells. Furthermore, the two- 
hybrid system has been designed so that the interaction 
of the SHZ domain with ligand can be post-translation- 
ally induced using estrogen and transcription can be 
easily monitored. We have developed two different two- 
hybrid systems. One is a ZAP-70 SHZ domain/TCR 5 
chain two-hybrid assay, a system designed to mimic the 
interaction of ZAP-70 with the TCR in activated T cells. 
We also designed a Src SHZ-domain-dependent two- 
hybrid assay. Here, we demonstrate chat compounds that 
selectively bind to the Src SHZ domain selectively 
inhibit Src, but not ZAP-70, SHZ-domain-dependent 
two-hybrid activity. The two-hybrid assay we describe 
can be used to monitor other SHZ-dependent interac- 
tions and hence could be used to identify inhibitors of 
other SHZ-domain-dependent processes. 
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Figure 2 
Schematic diagram of conditions tested for 
SHP-dependent two-hybrid formation in 
mammalian cells. HT1080 fibrosarcoma cells 
containing an integrated SEAP reporter gene 
were used for all transfections. SEAP gene 
transcription was GAL4-dependent because 
of the placement of five GAL4-binding sites 
and the IL-2 basal promoter upstream of 
SEAP coding sequences. Two different 
conditions were examined where the ZAP-70 
SH2-( ITAM interaction might occur. 
Transfections were carried using plasmids 
designed to produce the following proteins in 
cells: in (a) the ZAP-70 SH2 domains were 
fused to the GAL4 DNA-binding domain and 
the vSrc kinase-< was linked to the VP1 6 
transcriptional activation domain. In (b) vSrc 
kinase-[ residues were fused to the GAL4 
DNA-binding domain and the tandem ZAP 
SH2 domains were linked to the VP1 6 
transcriptional activation domain. The 
production of vSrc kinase-c fusion protein in 
one of these configurations was reasoned to 
lead to appropriately tyrosine phosphorylated 
5 chain residues. Only when fusion proteins 
were expressed as shown in (b) was there an 
induction of SEAP gene transcription. 
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Results and discussion 
We have employed a human HT1080 fibrosarcoma cell line 
(HT1080B), containing an integrated secreted alkaline 
phosphatase (SEAP) reporter gene under the control of a 
GAL4-responsive promoter to define conditions for moni- 
toring two-hybrid interactions. HT1080B does not normally 
produce SEAP (Figure la, mock). Transfection with an 
effector plasmid directing the expression of GALCDNA- 
binding-domain (GAL4DBD)-VPlh-transcriptional-activa- 
tion-domain fusion protein (GAL4-VP16) induces SEAP 
production (Figure la, GVP), demonstrating the potential 
utility of this cell line for detecting two-hybrid interactions. 
ZAP-70 SH2-domain-dependent two-hybrid assay 
The tyrosine residues within the 5 ITAM ligand must be 
phosphorylated for the ZAP-70 SH2 domains to bind with 
high affinity [17]. To facilitate phosphorylation of ITAM 
residues, the 5 chain was fused to the vSrc (viral Src) tyro- 
sine kinase domain (vSrc-c). We reasoned that the vSrc 
kinase domain, in this configuration, would appropriately 
phosphorylate, via an intramolecular or intermolecular 
interaction. the 5 chain. Two different orientations were 
tested for the ability to allow ZAP-70 SHZ-c two-hybrid 
formation. In one orientation, effector plasmids were con- 
structed such that one plasmid contained the ZAP-70 SHZ 
domains fused to the GAL4DBD with the other plasmid 
containing vSrc kinase-c fused to the \I’16 activation 
domain (Figure 2a). In the other orientation, the vSrc 
kinase-< was fused to the Gi\L4DBD and the tandem ZAP 
SH2 domains were fused to VP16 (Figure Zb). Neither 
GAL4ZAP-SH2 (Figure la, GZ22) nor the GAL4-vSrc- 
kinase-6 (Figure la, GSZ) fusion proteins. when expressed 
alone in cells. was capable of acting as a transcriptional acti- 
vator. In addition, the orientation shown in Figure 2a did 
not lead to transcriptional activation of the reporter gent 
(Figure la, GZ221\:PSZ). In contrast. the orientation 
shown in Figure 2b triggered a robust stimulation of SEAP 
gene transcription (Figure 1 a, GS%/\‘P%2). ‘l’ranscrip- 
tional activation did not occur if the \Src kinase-< residues 
were omitted (Figure la, (;/\‘PZ22). Furthermorc, 
GAL4DBD fusion proteins that contain the vSrc kinasc 
domain but lack the < residues (Figure 1 b. GS/vPZ22) or 
contain the c ITAhls but lack the \.Src kinase domain 
(GAL4DBD-I. data not shown) failed to induce transcrip- 
tional activation. Thus, the < chain. kinase and $3~2 
domains are required and must be positioned appropriately 
for two-hybrid formation to occur. ‘I’he results using 
HT1080B mammalian cell line were reproduced in yeast 
when using the appropriate analogous effector plasmids 
(data not shown). 
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Estrogen regulation of tandem ZAP-70 SH2 
domain-r two-hybrid formation in mammalian 
cells. Cells were transfected with effector 
plasmids and then cultured in media alone or 
supplemented with 10 nM estrogen for 18 h 
and the media were assayed for SEAP. The 
results shown are from a 1 h SEAP assay. The 
fusion proteins examined include GSZ 
(GAL4-Src-kinase-4 ITAM) and VPZ22 
(VP1 6-ZAP SH2 domains) and derivatives 
containing estrogen-receptor ligand-binding- 
domain residues, denoted GerSZ, VPerZ22 
and VPZ22er. 
Post-translational induction of SH2mdomain-dependent 
protein-protein interactions 
When assaying for inhibitors of specific protein-protein 
interactions, under certain conditions, it might be easier to 
block protein-protein interactions than disrupt a pre- 
formed complex [18]. This would be particularly relevant 
when dealing with high-affinity interactions or complexes 
with slow dissociation rates. Hence, the ability to induce a 
protein-protein interaction would be a useful feature of a 
cell-based screen for inhibitors of molecular interactions. 
Cells containing the components necessary for two-hybrid 
formation could first be exposed to potential inhibitory 
compounds and then protein-protein (two-hybrid) inter- 
action could be induced. To generate such a system, we 
fused the ligand-binding domain of a steroid hormone 
receptor to one of the binding partners. 
The modular ligand-binding domains of steroid hormone 
receptors have been widely used to generate protein 
chimeras that are ligand-dependent for activity [19,20]. The 
steroid hormone ligand-binding domain can act as a regula- 
tory domain and subject heterologous activities on the same 
polypeptide to hormonal control. To examine whether SHZ- 
domain-dependent two-hybrid formation can be hormonally 
controlled, we fused the ligand-binding domain of the estro- 
gen receptor (ER-LBD) to either the GAL4DBDvSrc- 
kinase-l; or the VPl6-tandem ZAP SH2 chimeric protein, 
and assayed for estrogen-inducible reporter-gene expression. 
We first examined the properties of a GAL4DBD-vSrc- 
kinase-l; fusion protein containing ER-LBD (GerSZ). 
Plasmids that direct the expression of GSZ or GerSZ were 
transfected into HT1080B reporter cells and then the cells 
were treated with 10 nM estrogen for 18 h. As shown in 
Figure 3, GerSZ is not, by itself, a transcriptional activator. 
Furthermore, neither GSZ or GerSZ fusion protein 
expressed alone activates SEAP production with estrogen 
treatment. Estrogen had no effect on SEAP production in 
cells with constitutive SHZ-domain-dependent two-hybrid 
formation (GSZ + VPZZZ). When cells expressing GerSZ 
and VP222 were cultured for 18 h in media containing 
10 nM estrogen, two-hybrid formation was induced, 
however, with a tenfold increase in SEAP production 
observed. In contrast, chimeric VP16-tandem-ZAP-SH2 
fusion proteins containing the ER-LBD at either of two 
positions were expressed in cells along with the GSZ fusion 
protein, estrogen regulation was not observed. Placement 
of the ER-LBD residues between the VP16 transcriptional 
activation domain and tandem ZAP SH2 abolished two- 
hybrid formation (Figure 3, GSZ + VPerZ22). When placed 
at carboxyl terminus of the protein, two-hybrid formation 
still occurred but estrogen regulation was not conferred 
(Figure 3, GSZ + VPZZZer). 
Src SHZ-domain-dependent two-hybrid assay 
Having defined conditions for the detection of tandem 
ZAP-70 SH2 binding in a mammalian cell-based two- 
hybrid assay format, we next investigated whether these 
conditions could be used to monitor other SHZ-domain- 
ligand interactions. Initially, we analyzed whether the Src 
SH2 domain can bind to the ligand recognized by the ZAP 
SH2 domains (the phosphorylated ITAM tyrosine residues 
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Conditions for Src SH2 domain-dependent two-hybrid formation in 
mammalian cells. Cells were transfected with the plasmids described 
in the text. Following transfection, cells were cultured for 24 h and the 
media were assayed for SEAP. Two separate transfections are shown 
(a,b), with the transfections shown in (b) performed in duplicate. The 
results shown are from a 3 h SEAP assay. GSZ, GAL4-Src-kinase-5 
ITAM; GSB, GAL4-Src-kinase-P ITAM; VPZ22, VP1 6-ZAP-SHP 
domains; VPSP, VP1 6-Src-SHP; VPS32, VP1 6-Src-SH3-SH2. 
VPS32(R178A) contains a mutation in the Src SH2 domain and 
VPS32(Y90A) and VPS32(P133L) each have a mutation in the Src 
SH3 domain predicted to dramatically reduce domain function. 
of the GALLiDBD-vSrc kinase-< fusion protein). Three 
VPlh-Src fusion proteins were prepared for this study: 
VP16-Src-SHZ-domain WPSZ), VPlMrc-SH3/SH2- 
domains (VPS32) and VP16-Src-SH3-domain (VPS3). VP% 
and VPS32 both contain the Src SHZ domain but in differ- 
ent contexts (alone or with the Src SH3 domain in its 
natural orientation). The VPS3 fusion protein should not 
bind to SHZ ligands and served as a control for the detec- 
tion of any SH3-domain-dependent interactions. Expres- 
sion plasmids for each of these proteins, as well as for 
VPZ22, were co-transfected into HT1080B reporter cells 
with a plasmid directing the expression of GAL4DBD-vSrc 
kinase-< ITAMs fusion protein (GSZ) and SEAP produc- 
tion was assessed. As shown in Figure 4a, VPS32 induced 
moderate SEAP production, whereas VPS2 and VPS3 failed 
to induce SEAP. 
Although the phosphorylated 5 subunit of the TCR is a 
high-affinity ligand for the ZAP-70 SH2 domains, a high- 
affinity consensus binding site for the Src SH2 domain 
(YEEI) is not present [21], hence phosphorylated 5 might 
not efficiently recruit VP16-Src-SH2-domain fusion pro- 
teins to the SEAP gene promoter. The chain of the IgE 
receptor encodes a high-affinity Src SHZ-domain-binding 
site, YEEL [22]. A plasmid directing the expression of 
GAL4DBD-v&c-kinase-P fusion protein (GSB) was made 
and tested in the two-hybrid assay. GSB expressed alone 
in HT1080B reporter cells did not activate SEAP reporter 
gene transcription (Figure 4a, GSB). The coexpression of 
GSB with either VP222 or VPS3 also failed to induce 
SEAP production. In contrast, coexpression of GSB with 
VPS32 or VPS2 induced SEAP production, although, the 
combination of GSB with VPS2 was approximately 13-fold 
less efficient than VPS32 in the assay. 
The finding that VP16 fusion proteins containing both the 
Src SH2 and SH3 domains induce SEAP production more 
efficiently than VP16-SH2 suggested that there might be 
weak binding sites for the Src SH3 domain in the GSB 
fusion protein. To delineate the contributions that the Src 
SH2 and Src SH3 domains make to GSB-dependent two- 
hybrid formation, amino-acid substitutions were made in 
the VPS32 fusion protein that should dramatically affect 
SHZ- or SH3-domain binding. As shown in Figure 4b, a 
mutation in the phosphotyrosine-binding pocket of the 
Src SH2 domain (Arg178-+Ala, R178A [23]) abolished 
two-hybrid formation/SEAP production. In contrast, muta- 
tions in the SH3 domain that have been shown previously 
to affect ligand binding (Tyr90-+Ala, Y90A, and 
Prol33+Leu, P133L [24]), did not reduce SEAP produc- 
tion. These experiments support the hypothesis that GSB- 
dependent two-hybrid formation is Src SH2-dependent. 
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Estrogen-regulated two-hybrid stable cell lines. Cells were co- 
transfected with a plasmid conferring neomycin resistance and with 
plasmids directing the expression of either GerSB + VPZ22, GerSB + 
VPSP or GerSB + VPS32. Colonies were selected, expanded and 
analyzed for estrogen-dependent SEAP production. Of the 12 ZAP-70 
SH2 cell lines analyzed, two were estrogen-dependent for SEAP 
induction. Of the 24 Src SH2 cell lines screened, two were positive for 
estrogen-dependent SEAP activity and of the 12 Src SH3/SH2 cell 
lines screened, three scored positive. Representative results obtained 
examining estrogen-dependent SEAP production using ZAP-70 SH2 
(GerSG + VPZ22), Src SH2 (GerSB + VPSP) and Src SH3/SH2 
(GerSB + VPS32) cell lines are shown. The results shown are from a 
1 h SEAP &say. 
The addition of the SH3 domain to the fusion protein 
(VPS32) could lead to more efficient SEAP production 
because the protein might be more stable in cells than the 
VP16-Src SHZ fusion protein or the presence of the SH3 
domain in the VP16SH3/SHZ fusion protein might con- 
tribute to SHZ-domain binding or folding. 
Construction and use of mammalian cell lines for the 
identification of cell-permeant SH2 domain inhibitors 
We have described conditions for regulated SHZ-domain- 
dependent two-hybrid formation in mammalian cells, 
which should be useful for the identification of com- 
pounds that inhibit SH2-domain-ligand interactions. One 
technical problem with the assay described above, 
however, is that the effector plasmids have been intro- 
duced into cells by transient transfection. This would not 
be practical for a routine screening assay, as large-scale 
transfections are cumbersome and too variable. Because 
a reproducible, robust, high-throughput assay requires 
stable cell lines, the effector plasmids were stably inte- 
grated into HT1080B reporter cells. To first test if it 
would be possible to generate a stable estrogen-inducible 
SEAP-producing cell line, HT1080B cells were co-trans- 
fected with a plasmid that directs the constitutive expres- 
sion of GAL4DBD-ER-LBD-VP16 activation-domain 
fusion protein (GerVP) and a second plasmid that confers 
neomycin resistance. Stable neomycin-resistant trans- 
fected cells were expanded and tested for estrogen- 
dependent SEAP production. The results for one cell line 
are shown in Figure 5 (GerVP). This cell line produced 
high levels of SEAP in an estrogen-dependent manner. 
Having demonstrated that the stable selection of estrogen- 
inducible SEAP cell lines was possible using HTlO8OB 
reporter cells, transfections were then carried out to select 
cells that would have estrogen-regulated ZAP-70 SH2- 
and Src SH2-dependent two-hybrid formation. Represen- 
tative results obtained examining estrogen-dependent 
SEAP production using ZAP-70 SH2 (GerSZ + VPZZZ), Src 
SH2 (GerSB + VPS2) and Src SH3/SH2 (GerSB + VPS32) 
cell lines are shown in Figure 5. Both ZAP SH2- and Src 
SHZdependent estrogen-regulated two-hybrid stable cell 
lines were obtained. 
To determine whether the two-hybrid cell lines would be 
useful for the identification of SH2-domain inhibitors, we 
synthesized a high affinity Src SH2 ligand and the corre- 
sponding ester prodrug [25], a derivative shown to have 
increased cell permeability (Figure 6). When tested in vitro 
using fluorescence polarization [26], the parent compound 
had an IC,, of 4-9 FM for the Src SH2 domain and exhib- 
ited an IC,, of >lOOO PM for ZAP-70 SH2 domains. As 
expected, the prodrug did not exhibit any binding activity 
in the in vitro assays. Both compounds were tested for their 
effect on inhibiting the production of SEAP from the 
GerVP, ZAP SHZ-5 ITAM and Src SH2-/3 ITAM cell lines 
(Figure 7). Alamar blue reactivity or 3H-uridine incorpora- 
tion were monitored to determine if the compounds non- 
specifically inhibited transcription or were toxic to cells. 
Both the parent compound (Figure 7a,b) and prodrug 
(Figure 7c,d) significantly inhibited SEAP production from 
the Src SH2-P ITAM cell line. The parent compound had 
an IC,, of 150 PM in the Src SH2 two hybrid cell line with 
little or no inhibition of the ZAP or GerVP cells at 200 PM. 
The prodrug was a more effective inhibitor with an IC,, of 
18 yM in the Src SH2 two-hybrid cells. In contrast, this 
compound had an IC,, of 60-70 PM in the ZAP and GerVP 
two-hybrid cells, which overlapped in a concentration- 
dependent manner with inhibition of 3H-uridine incorpo- 
ration and alamar reactivity. Thus, the concentrations of 
prodrug that inhibit SEAP production from the ZAP and 
GVP cells correlate with nonspecific inhibition of transcrip- 
tion or toxicity. ‘The higher potency exhibited by the 
prodrug compared to the parent compound in the Src SH2 
cell line is probably due to increased cellular permeability. 
It is noted that the parent compound contains three nega- 
tive charges and still demonstrates inhibitory activity in the 
two-hybrid cells. We believe that even small amounts of 
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Compounds that bind to the Src SH2 domain. 
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Two Src SH2 domain binding compounds, 
Ac-(4-(difluorophosphonomethyl))-L- 
Phe-L-Glu-N(methyl)(cyclohexylpropyl) (1) 
and the bis(pivaloxymethyl) prodrug (2). 
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highly charged compounds can enter the cells via pinocyto- 
sis, particularly as the cells are incubated with compound 
for a relatively long duration (20 h). It is also of note that 
this compound is relatively lipophilic, potentially compen- 
sating for poor membrane permeability exerted by the high 
overall charge. We have compared the effects of several 
structurally similar compounds containing an equivalent 
negative charge and with different IC,, values in the in 
vitro binding assay. We have found a direct relationship 
between the extent of inhibition of SHZ binding in vitro 
and the inhibition measured in the two-hybrid system. 
Therapeutic agents that specifically target proteins whose 
functions are unique and critical for particular disease 
states offer the potential of reduced side effects. New cel- 
lular assays with target-dependent readouts would facili- 
tate the identification of such agents. In this report, we 
have described a novel two-hybrid assay using human 
components in mammalian cells, where specific SHZ- 
domain-ligand interactions control the expression of a 
reporter gene. Stable cell lines have been constructed in 
which the association of the human ZAP-70 or Src SHZ 
domains with a phosphorylated ligand can be induced and 
readily monitored. These cells form the basis of an assay 
to identify cell-permeant inhibitors of SHZ-mediated 
interactions. In contrast to target cell assays (e.g., using 
T cells or osteoclasts), in which an inhibitor can interfere 
with the assay readout at many points in a pathway, these 
assays are dependent on the target interaction of interest. 
Compounds that selectively inhibit the Src SHZ domain 
might be useful for the treatment of osteoporosis. ZAP 
SH2 domain inhibitors would be expected to be selective 
T-cell inhibitors. 
Configuring the mechanism-based two-hybrid assay in a 
mammalian cell offers a number of advantages over a 
yeast-based system. First, as the cellular permeability of 
compounds into human and yeast cells does not always 
correlate, the mammalian cell assay might identify active 
compounds that would not be detected in a yeast cell 
assay. Second, the mammalian cell could contain auxiliary 
factors that stabilize or activate the protein of interest. In 
addition, the mammalian cell might tolerate certain 
aspects of the assay, such as the requirement for a protein 
that is difficult to express or toxic in a yeast cell. 
The development of the SHZ-domain-based two-hybrid 
assay was complicated by the need to phosphorylate the 
ligand. In contrast to the ‘tri-hybrid’ system reported in 
yeast [27], we solved the problem by linking the ligand 
and kinase within the DNA-binding-domain fusion. This 
orientation appears to be critical. because the reverse ori- 
entation, with the kinase and ligand linked to the activa- 
tion domain, failed to express SEAP. Similarly, the ability 
to hormonally regulate the system was context dependent. 
The estrogen receptor ligand-binding domain conferred 
regulation when linked to the DNA-binding-domain 
fusion but not when part of the activation-domain fusion 
protein. The mechanism of this context dependence is not 
understood and our results suggest that, in general, multi- 
ple experimental designs must be explored to define con- 
ditions for two-hybrid formation. The ability to 
post-translationally regulate fusion proteins could find 
general application to evaluate protein-protein interac- 
tions in mammalian cells dependent on serine/threonine 
phosphorylation, acetylation. or perhaps proteolysis. 
We have shown that the SHZ mechanism-based assay can 
be used to detect Src SHZ domain inhibitors. The speci- 
ficity of action of these inhibitors has been assessed by 
testing for nonspecific effects on transcription (ZH-uridine 
incorporation) and cell viability (alamar blue reactivity) 
and by using other appropriately engineered cell lines as 
counterscreens. For example, general inhibitory effects on 
translation, secretion, GAL4 DNA binding or ER-LBD 
function would be identified when using cells that 
produce SEAP under the control of a GAL4-ER- 
LBD-VP16 transcription factor. Src-kinase inhibitors 
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should similarly affect both the Src and ZAP SH2 two- 
hybrid cells. Cell lines in which two-hybrid formation is 
dependent on the SH2 domains from Syk and Fyn have 
been constructed (data not shown). These and additional 
cell lines could be used to assess the specificity of a com- 
pound for a particular SHZ domain. 
In a manner similar to that described here, we have 
designed a Src SH3 mechanism-based mammalian cell 
assay to identify compounds that block Src SH3 binding. 
The affinity of SH3 domain interactions is lO-loo-fold 
lower than that observed with SHZ domains [28]. To detect 
lower affinity interactions, we expressed the SH3 domain in 
a novel manner, linked to bundled transcriptional activation 
domains (R.J.R. and S. Natesan, unpublished observations). 
By increasing the number of cognate DNA-binding sites in 
the reporter-gene promoter [29] or by increasing the 
strength of the transcriptional-activation domain fusion 
protein (data not shown), the sensitivity of detection of two- 
hybrid protein-protein interactions could also be improved, 
allowing the detection of weak protein-protein interactions. 
Significance 
We have described an SH2 mechanism-based two-hybrid 
assay using mammalian cells. This assay will be useful as 
a screen for antagonists of SH2-mediated protein-protein 
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interactions that mediate disease states in humans. Cells 
can be cultured and all assay steps performed using 96- 
well dishes, convenient for high-throughput screening 
purposes. Using the appropriate cell lines, counter- 
screens can be designed to address the specificity of 
inhibitor action. The assay can provide rapid structure- 
activity relationship information, taking into account not 
just binding, but also cell membrane permeability. Mech- 
anism-based assays might have general utility as a screen 
for inhibitors of specific protein-protein interactions and 
could be particularly useful when performing cellular 
screens for inhibitory compounds using protein domains 
where binding partners have been identified but cellular 
functional assays are not yet available. 
Materials and methods 
Plasmid constructions 
The retroviral vector pLH, which contains the Hygromycin B resistance 
gene (hph) driven by the Moloney murine leukemia virus LTR and a 
unique downstream C/al site, was constructed as follows: pWZL-Bleo (a 
gift of J. Morganstern) was cut with BamHl and C/al to release the bleo 
gene and a HindIll-C/al fragment, from pBabe-Hygro 1301, containing the 
hph gene was inserted. pLH-5xGAL4-IL2SEAP was created by cloning 
a C/al-BstBI fragment from 5xGAL4-IL2SEAP, which contains five 
GAL4 sites upstream of a minimal IL2 promoter driving expression of the 
SEAP gene (a gift of J. Morganstern and S. Ho) into the C/al site of pLH. 
It was oriented such that the directions of transcription from the viral LTR 
and the internal GAL4-IL2 promoters are the same. The properties of 
SHP-domain- and vSrc-kinase-ITAM fusion proteins were first examined 
by expression in yeast (R.J.R., unpublished observations). Sequences 
encoding SH2 domains and vSrc kinase-ITAM residues were then shut- 
tled from the yeast expression plasmids into mammalian cell expression 
vectors for transfection into the HTlO8OB reporter cell line. Two mam- 
malian cell expression plasmids were use in this study for the production 
of novel fusion proteins. pBXG1 directs the expression of GAL4 DNA- 
binding domain fusion proteins in mammalian cells. pBXG1 is a 
pECE72-based vector [31 I. pECE72 has the SV40 virus origin of repli- 
cation, SV40 early promoter and SV40 polyadenylation regulatory 
sequences. GAL4 (l-147) and multiple cloning sites C-terminal to 
GAL4 coding sequences were obtained from pSKGAL147 [32] as a 
HindllllXbal fragment and inserted into HindllllXbal cut pECE72 to 
generate pBXG1. pMVN1 (kindly provided by I. Sadowski) was used for 
the production of transcriptional activation domain fusion proteins in 
mammalian cells. pMVN1 contains the SV40 early promoter, HSV TK 
translational leader, SV40 nuclear localization sequences and VP1 6 acti- 
vation domain residues followed by multiple cloning sites for the con- 
struction of novel fusion proteins. Residues 248-526 of the vSrc kinase 
(Genbank Accession #JO2342) domain was placed downstream of 
GAL4 DNA binding domain or transcriptional activation domain 
sequences. Sequences encoding residues 52-l 64 of the human Zeta 
chain (Genbank Accession # JO41 32) or sequences encoding residues 
203-244 of the human Beta ITAM were then placed 3’ to the vSrc 
kinase DNA. Sequences encoding residues l-259 of human ZAP-70 (a 
gift of M. Botfield, Genebank Accession #LO5148), 144-249 of Src 
(SH2) or 84-249 of Src (SH3/SH2) were used for the construction of 
SH2 domain fusion proteins [331. VPS3 contains Src residues 84-l 43. 
The ER-LBD consrsts of residues 282-595 of the human estrogen 
receptor (Genbank Accession #Ml 2674). Additional details about the 
constructs described in this report are available by request. 
Cell culture 
HT1080 cells (ATCC CCL-l 21), derived from a human fibrosarcoma, 
were grown in MEM supplemented with nonessential amino acids 
and 10% Fetal Bovine Serum. Helper-free retroviruses containing the 
SxGAL4-IL2-SEAP reporter gene were generated by transient 
co-transfection of 293T cells [341 with a Psi(-) amphotropic packaging 
vector (a gifl of D. Afar and 0. Witte) and the retroviral vector pLH- 
5xGAL4-IL2SEAP. To generate a clonal cell line containing the SEAP 
reporter gene stably integrated, HT1080B cells infected with retroviral 
stock were diluted and selected in the presence of 300 pg/ml 
Hygromycin B. Individual clones were screened for the presence of inte- 
grated reporter gene by transient transfection of a plasmid encoding a 
chimeric transcription factor containing a GAL47DNA-binding domain. 
The most responsive clone was used for subsequent analysis. Cells 
were plated in six-well dishes (1 x lo6 cells/well) and transfected with 
Lipofectamine (GIBCOIBRL) using the manufacturers recommended 
conditions. A total of 2.5 ug of DNA was transfected into each well: 
1 ug GAL4 DNA-binding domain fusion protein, 1 pg VP16 activation 
domain fusion protein and 0.5 pg pUCl9. Following lipofection (16 h), 
1 ml of fresh media was added to each well. After 18-24 h, media was 
removed and assayed for SEAP as described [351 using a Luminesence 
Spectrometer (Perkin Elmer) at 350 nm excitation and 450 nm emission. 
If estrogen inducible SEAP production was to be examined, after 
removal of media containing lipofectamine, cells received 1 ml of fresh 
media containing 10 nM P-estradiol. Each transient transfection result 
has been reproduced at least twice and the results of a representative 
experiment are shown. The P-estradiol (Sigma Chemicals) was stored 
as a 10 mM stock solution in 100% ethanol and diluted just before use. 
Stable cell lines were generated by co-transfection of reporter cells with 
effector plasmids and pBabeNeo [301 and selected in medium contain- 
ing 500 ug/ml Geneticin (GIBCO BRL). 
Two-hybrid assay protocol 
Stable transfected two-hybrid cells were plated into 96-well plates at 
20,000 cells/well in 100 ul culture medium and then incubated for 4 h at 
‘37°C and 5% CO,. Test compounds were then added at the appropri- 
ate concentration with each well containing a final concentration of 
dimethyl sulfoxide (DMSO) equivalent to O.lo/,. Untreated control 
samples contained culture medium supplemented with 0.1% DMSO. 
Compounds were tested in triplicate wells. Cells were incubated with 
compound for 3 h at 37°C and 5% CO, followed by the addition of 
estrogen at a final concentration of 1 PM. Cells were then incubated for 
an additional t 6 h at 37°C and 5% CO,. Cell-culture supernatant was 
collected and heat inactivated at 65% for 60 min to inactivate back- 
ground phosphatase activity. The remaining monolayer of cells was mon- 
itored for alamar reactivity or 3H-uridine incorporation. Heat-inactivated 
supernatants from the various two-hybrid cells lines were transferred into 
a 96-well fluorimeter plate (Perkin Elmer) and monitored for SEAP activ- 
ity by incubating with 0.66 mM 4-methylumbelliferylphosphate and 1 M 
diethanolamine at 37%. Samples were analyzed on a Perkin-Elmer 
LS5OB fluorimeter using an excitation of 350 nM and an emission of 
445 nM. Cells were monitored for alamar reactivity by incubating cells 
with 100 @well of alamar blue (Alamar Biosciences, Sacramento, CA) 
diluted 1 :lO in culture medium for 2-4 h at 37°C. Alternatively, cells 
were monitored for 3H-uridine incorporation by incubating cells with 
4 @/ml 3H-5,6-uridine (NEN DuPont) for 90 min, washing cells three 
times with ice-cold phosphate -buffered saline (PBS), lysing cells with 
0.2 N sodium hydroxide and then immediately adding ice cold trichlo- 
racetic acid (TCA) to a final concentration of 20%. Lysed and TCA pre- 
cipitated cells were harvested onto filter mats using a TomTec (Wallac, 
Gaithersburg, MD) cell harvester and incorporated 3H-5,6-uridine was 
quantitated using a Betaplate reader (Wallac, Gaithersburg, MD). 
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